Sativa Flowers CBD Tincture Oil GMP 20% Nonintoxicating Compound

Health Supplements CBD Raw Material CBD Oil Products Specification 5%-30%

(CBD) Oils Are Low Tetrahydrocannabinol Products Derived from Sativa

That Have Become Very Popular Over The Past Few Years. Patients Report Relief for a Variety

of Conditions, particularly Pain, Without the Intoxicating Adverse Effects of Medical Marijuana.

In June 2018, The First CBD-Based Drug, Epidiolex, Was Approved by The Us Food and Drug

Administration for Treatment of Rare, Severe Epilepsy, Further Putting The Spotlight on CBD

and Oils. There is a growing Body of Prelinical and Clinical Evidence to support Use of

CBD Oils for Many Conditions, Suggesting ITS Potential Role as Another Option for Treating

Challenging Chronic Pain Or Opioid Addiction. Care Must Be Taken When Direction Patants

Toward CBD Products Because There Is Little Regulation, And Studies Have Found Inaccurate

Labeling of CBD and Tetrahydrocannabinol Quantities. This article provides an overview of the

scientific work on cannabinoids, cbd, and oil and the distinction Between Marijuana, ,

and the Different Components of CBD and Oil Products.

We Summarize The Current Legal Status Of CBD And Oils In The United States And Provide

to Guide to Identifying Higher-Quality Products So That Clinicians Can Advise Their Patants on The

Safest and Most Evidence-Based Formulations. This review is based on Pubmed Search Using The

Terms CBD, , Oil, And Medical Marijuana. Articles Were Screened for Relevance,

and Those With The Most Up-to-Date Information Were Selected For Inclusion.

(CBD) is a Nonintoxicating Compound Extracted from Sativa Plants That Has

Gained Popularity for Medical Use Ranging from Epilepsy to Pain Control and Addiction Treatment

Because of Sits Differing Mechanism of Action from Marijuana and SafeTy Profile.

Although Implinical and Pilot Human Studies Have Suggested to Potential Role for CBD in Numberful

Clinical Situations, Thorough Clinical Studies Have Only Been Performed on IntraTable Epileepsy

Syndromes for Which Epidiolex, A CBD Drug, Was Approved by The US Food and Drug Administration

For Use.

The Legal Landscape of CBD Remains Complex Because of Differing State and Federal Laws

Giving Access to Medical and Marijuana Products.

The CBD and OIL PRODUCT MARKET REMAINS A Concerning One Because of Noted

Variability in CBD and TETRAHYDROCANNABINOL LEVELS IN PRODUCTS, AS WELL AS

LACK OF REGULATION IN PRODUCTION AND DISTRIBUTION.

Although CBD and Oils Remain An Unproven Therapeutic Option, Physicians Should

Remain Open To The Possible Future Role These Products May Play in The Management

of A Variety of Difficult to Treat Designs, in particular Pain and Addiction Treatment in the

context of the opioid crisis.